These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17327293)

  • 1. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir.
    Rossi L; Franchetti P; Pierigé F; Cappellacci L; Serafini S; Balestra E; Perno CF; Grifantini M; Caliò R; Magnani M
    J Antimicrob Chemother; 2007 Apr; 59(4):666-75. PubMed ID: 17327293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of lamivudine and tenofovir.
    Franchetti P; Cappellacci L; Petrelli R; Vita P; Grifantini M; Rossi L; Pierigé F; Serafini S; Magnani M; Balestra E; Perno CF
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):953-7. PubMed ID: 18058516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
    Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
    Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphono methoxypropyl)adenine.
    Franchetti P; Rossi L; Cappellacci L; Pasqualini M; Grifantini M; Balestra E; Forbici F; Perno CF; Serafini S; Magnani M
    Antivir Chem Chemother; 2001 May; 12(3):151-9. PubMed ID: 12959323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
    Miller MD; Margot NA; Hertogs K; Larder B; Miller V
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1025-8. PubMed ID: 11562951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular pharmacology of emtricitabine and tenofovir.
    Stevens RC; Blum MR; Rousseau FS; Kearney BP
    Clin Infect Dis; 2004 Sep; 39(6):877-8; author reply 878-9. PubMed ID: 15472830
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
    Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
    Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir.
    Rossi L; Brandi G; Schiavano GF; Balestra E; Millo E; Scarfi S; Damonte G; Gasparini A; Magnani M; Perno CF; Benatti U; De Flora A
    AIDS Res Hum Retroviruses; 1998 Mar; 14(5):435-44. PubMed ID: 9546803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
    Marchand B; White KL; Ly JK; Margot NA; Wang R; McDermott M; Miller MD; Götte M
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2911-9. PubMed ID: 17517852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
    Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.
    Magnani M; Balestra E; Fraternale A; Aquaro S; Paiardini M; Cervasi B; Casabianca A; Garaci E; Perno CF
    J Leukoc Biol; 2003 Nov; 74(5):764-71. PubMed ID: 12960277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of the acyclic nucleoside phosphonate tenofovir toward human T-cell leukemia/lymphotropic virus type 1 infection of human peripheral blood mononuclear cells in vitro.
    Balestrieri E; Sciortino MT; Mastino A; Macchi B
    Antiviral Res; 2005 Dec; 68(3):154-62. PubMed ID: 16271772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5'-phosphonate derivatives of 2',3'-dideoxy-3'-thiacytidine as new anti-HIV prodrugs.
    Khandazhinskaya AL; Jasko MV; Karpenko IL; Solyev PN; Golubeva NA; Kukhanova MK
    Chem Biol Drug Des; 2011 Jul; 78(1):50-6. PubMed ID: 21518262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
    Mackman RL; Boojamra CG; Prasad V; Zhang L; Lin KY; Petrakovsky O; Babusis D; Chen J; Douglas J; Grant D; Hui HC; Kim CU; Markevitch DY; Vela J; Ray A; Cihlar T
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6785-9. PubMed ID: 18029175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies towards HIV-1 infection in macrophages.
    Perno CF; Svicher V; Schols D; Pollicita M; Balzarini J; Aquaro S
    Antiviral Res; 2006 Sep; 71(2-3):293-300. PubMed ID: 16806514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
    Anastasi C; Hantz O; De Clercq E; Pannecouque C; Clayette P; Dereuddre-Bosquet N; Dormont D; Gondois-Rey F; Hirsch I; Kraus JL
    J Med Chem; 2004 Feb; 47(5):1183-92. PubMed ID: 14971898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus.
    Franchetti P; Abu Sheikha G; Cappellacci L; Marchetti S; Grifantini M; Balestra E; Perno C; Benatti U; Brandi G; Rossi L; Magnani M
    Antiviral Res; 2000 Sep; 47(3):149-58. PubMed ID: 10974367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.